| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Xavier Adhoute, Marie De Matharel, Laurent Mineur, Guillaume Pénaranda, Dann Ouizeman, Clemence Toullec, Albert Tran, Paul Castellani, Armelle Rollet, Valérie Oules, Hervé Perrier, Si Nafa Si Ahmed, Marc Bourliere and Rodolphe Anty |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Xavier Adhoute, PhD, Doctor, Doctor, Department of Gastroenterology and Hepatology, Hôpital Saint-Joseph, 26 Bd Louvain, Marseille 13000, France. xvadhoute@gmail.com |
| Key Words |
Hepatocellular carcinoma; Regorafenib; Cabozantinib; C-reactive protein; Neutrophil-lymphocyte ratio |
| Core Tip |
One limited population of advanced hepatocellular carcinoma patients has sustained disease control using tyrosine kinase inhibitors (TKIs) as first-line systemic therapy. Patients with preserved liver function and performance status progress to second-line systemic therapy. Only two broad-spectrum TKIs are approved for this indication in France, and no direct comparative studies are available. Immune checkpoint inhibitors are currently the standard of care as first-line therapy in combination with an anti-angiogenic agent and will most likely change the treatment strategy of second-line therapy. No biomarkers are available to guide treatment, but serum inflammation-related factors may provide additional support. |
| Publish Date |
2022-08-10 13:14 |
| Citation |
Adhoute X, De Matharel M, Mineur L, Pénaranda G, Ouizeman D, Toullec C, Tran A, Castellani P, Rollet A, Oules V, Perrier H, Si Ahmed SN, Bourliere M, Anty R. Second-line therapy for advanced hepatocellular carcinoma with regorafenib or cabozantinib: Multicenter French clinical experience in real-life after matching. World J Gastrointest Oncol 2022; 14(8): 1510-1527 |
| URL |
https://www.wjgnet.com/1948-5204/full/v14/i8/1510.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v14.i8.1510 |
